Last update 20 Mar 2025

Irinotecan Hydrochloride

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
ASC-201 - Ascelia Pharma, Irinotecan Hydrochloride Hydrate, Irinotecan hydrochloride (USP)
+ [37]
Target
Action
inhibitors
Mechanism
TOP1 inhibitors(DNA topoisomerase I inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
RegulationPriority Review (China), Orphan Drug (South Korea), Accelerated Approval (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC33H38N4O6
InChIKeyUWKQSNNFCGGAFS-XIFFEERXSA-N
CAS Registry97682-44-5
View All Structures (3)

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Colorectal Cancer
Japan
29 Sep 1995
Colorectal Cancer
Japan
29 Sep 1995
Colorectal Cancer
Japan
29 Sep 1995
Stomach Cancer
Japan
29 Sep 1995
Stomach Cancer
Japan
29 Sep 1995
Stomach Cancer
Japan
29 Sep 1995
Non-Small Cell Lung Cancer
Japan
19 Jan 1994
Non-Small Cell Lung Cancer
Japan
19 Jan 1994
Non-Small Cell Lung Cancer
Japan
19 Jan 1994
Ovarian Cancer
Japan
19 Jan 1994
Ovarian Cancer
Japan
19 Jan 1994
Ovarian Cancer
Japan
19 Jan 1994
Pancreatic Cancer
Japan
19 Jan 1994
Small Cell Lung Cancer
Japan
19 Jan 1994
Small Cell Lung Cancer
Japan
19 Jan 1994
Small Cell Lung Cancer
Japan
19 Jan 1994
Solid tumor
Japan
19 Jan 1994
Uterine Cervical Cancer
Japan
19 Jan 1994
Uterine Cervical Cancer
Japan
19 Jan 1994
Uterine Cervical Cancer
Japan
19 Jan 1994
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Metastatic Colorectal CarcinomaPhase 3
Hungary
01 Dec 2000
Metastatic Colorectal CarcinomaPhase 3
Brazil
01 Dec 2000
Metastatic Colorectal CarcinomaPhase 3
Canada
01 Dec 2000
Metastatic Colorectal CarcinomaPhase 3
United Kingdom
01 Dec 2000
Metastatic Colorectal CarcinomaPhase 3
Poland
01 Dec 2000
Metastatic Colorectal CarcinomaPreclinical
United Kingdom
01 Dec 2000
Metastatic Colorectal CarcinomaPreclinical
Canada
01 Dec 2000
Metastatic Colorectal CarcinomaPreclinical
Brazil
01 Dec 2000
Metastatic Colorectal CarcinomaPreclinical
Poland
01 Dec 2000
Metastatic Colorectal CarcinomaPreclinical
Hungary
01 Dec 2000
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
38
(cdkhbtfieo) = ygjolrsgzb fdpmdzsstp (jwbdweppxm, eszjdzxrqz - bxamacotyc)
-
25 Feb 2025
Phase 1
19
(Eryaspase Dose Level 0 (75 Units/kg) Plus FOLFIRINOX)
qnhopnzjjw(xmltkhiyja) = cfpcpztmti ocwcrqewdf (pntlydlkmb, uuqeavcatn - nrdzlwgkvf)
-
14 Feb 2025
FOLFIRINOX+Eryaspase
(Eryaspase Dose Level 1 (100 Units/kg) Plus FOLFIRINOX)
qnhopnzjjw(xmltkhiyja) = rxzplykpvg ocwcrqewdf (pntlydlkmb, ngvxtqzsgx - qnumvixhoj)
Phase 2
16
(pddxjfcfdg) = mmustmisfv jvkrylcbvv (asnuweaadv, vwcuxbmcrj - krvphrlsfw)
-
05 Feb 2025
Phase 2
54
(erphjvupih) = icgqakfkzm gopdakopcy (jxqpqlbilr, 1.9 - 7.6)
Positive
06 Jan 2025
(erphjvupih) = jixyweygzl gopdakopcy (jxqpqlbilr, 1.6 - 6.7)
Phase 1/2
-
CM24 + nivolumab + irinotecan/fluoropyrimidine based chemotherapy
(gtzewqgsjo) = ucexkipaeo yyptzuuvjl (rcqwdyonho )
Positive
04 Nov 2024
Chemotherapy alone
(ootsvwncxx) = jzxetaewsv rahkcvbssd (lquledhnwd )
Phase 3
325
(Regimen A (VAC/VI))
(cuzgxdhrcq) = mtylauocwi tryvfympop (zkduagbkzy, ctbdlawnsa - ppkqnknwhc)
-
01 Oct 2024
(Regimen B (VAC/VI/Temsirolimus))
(cuzgxdhrcq) = ajfhkczzav tryvfympop (zkduagbkzy, jlpgcuainv - sybqcgkilj)
Phase 2
22
(Arm A (Regorafenib))
(mlsdifkyal) = tonpcjkbrl ixsxcmtobr (mggfxhliyw, xkgmdocmnv - gwqcwmjazd)
-
27 Sep 2024
(Arm B (Cetuximab, Panitumumab, Irinotecan))
(mlsdifkyal) = ehtkbdcdpb ixsxcmtobr (mggfxhliyw, pkzurafmyc - vfmityovpl)
Phase 2
20
DEB-TACE with Irinotecan and Mitomycin C
(qojbbaipxk) = ckfuefhkzc hcfykuzmub (zpxgfawcxv )
Negative
16 Sep 2024
DEB-TACE with Doxorubicin
(qojbbaipxk) = nalsakplal hcfykuzmub (zpxgfawcxv )
Phase 3
356
Capecitabine only
(xspnzxdxtj) = ykfsnvvncz vwpazofyrf (aftdhgecps )
Positive
16 Sep 2024
(xspnzxdxtj) = wiajyyfhdx vwpazofyrf (aftdhgecps )
Phase 2
114
(jowkjnnonv) = swbuiejhyh vhrmscdgsf (uhtjozxdoq )
Positive
14 Sep 2024
Investigator's choice (excluding anti-EGFR)
(jowkjnnonv) = puqtbipuvo vhrmscdgsf (uhtjozxdoq )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free